Table 3.

Treatment modality for patients who experienced recurrence or progression under HIVEC^® treatment (N = 26)

Treatment modality	No of patients (%)
Recurrent disease (N = 22)
Radical Cystectomy	11 (50%)
Planned for Radical Cystectomy	1 (4%)
BCG rechallenge	4 (19%)
Endoscopic surveillance	4 (19%)
Curative external beam radiotherapy	1 (4%)
Intravesical gemcitabine	1 (4%)
Progressive disease (N = 4)
Neo-adjuvant chemotherapy	1 (25%)
Palliative chemotherapy	1 (25%)
Palliative chemotherapy + radiotherapy	1 (25%)
Best supportive care	1 (25%)